Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lisata Therapeutics Inc LSTA

Healthcare Biotechnology
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to... see more

Recent & Breaking News (NDAQ:LSTA)

Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for 'Specialized BioTherapeutics Company of the Year'

GlobeNewswire 2 days ago

Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 9 days ago

Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration

GlobeNewswire November 6, 2024

Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024

GlobeNewswire November 6, 2024

Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events

GlobeNewswire October 31, 2024

Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis

GlobeNewswire October 28, 2024

Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events

GlobeNewswire October 3, 2024

Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial

GlobeNewswire September 17, 2024

Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events

GlobeNewswire September 9, 2024

Lisata Therapeutics' Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma

GlobeNewswire September 5, 2024

Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire August 12, 2024

Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024

GlobeNewswire August 5, 2024

Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD(TM) Technology to Evaluate Efficacy of Pancreatic Cancer Therapy

GlobeNewswire July 18, 2024

Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma

GlobeNewswire July 16, 2024

Lisata Therapeutics' Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model

GlobeNewswire July 10, 2024

Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial

GlobeNewswire June 13, 2024

Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events

GlobeNewswire May 28, 2024

Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer

GlobeNewswire May 20, 2024

Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire May 9, 2024

Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events

GlobeNewswire May 8, 2024